Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Crimean-Congo Hemorrhagic Fever (CCHF) is a severe tick-borne disease, endemic in many countries in Africa, the Middle East, Eastern Europe and Asia. Between 15-70% of reported cases are fatal with no approved vaccine available. In the present study, the attenuated poxvirus vector, Modified Vaccinia virus Ankara, was used to develop a recombinant candidate vaccine expressing the CCHF virus nucleoprotein. Cellular and humoral immunogenicity was confirmed in 2 mouse strains, including type I interferon receptor knockout mice, which are susceptible to CCHF disease. Despite the immune responses generated post-immunisation, the vaccine failed to protect animals from lethal disease in a challenge model.

Original publication




Journal article


Human vaccines & immunotherapeutics

Publication Date





519 - 527


a Public Health England ; Porton Down; Salisbury , Wiltshire , UK.


Cell Line, Vero Cells, Chick Embryo, Animals, Mice, Knockout, Humans, Mice, Hemorrhagic Fever Virus, Crimean-Congo, Hemorrhagic Fever, Crimean, Nucleoproteins, Vaccines, Synthetic, Viral Proteins, Viral Vaccines, Antibodies, Viral, Immunization, Viral Load, Cricetinae, Receptor, Interferon alpha-beta, Immunogenicity, Vaccine, Chlorocebus aethiops